{
  "trial_id": "NCT00314366",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "consented to the study and extensive baseline testing will be completed at St. Luke's Episcopal Hospital in Houston, Texas.",
      "label": "met"
    },
    {
      "criterion": "his/her own bone marrow harvested and later injected, if randomized to receive active treatment.",
      "label": "unknown"
    },
    {
      "criterion": "NOGA mapping is performed and the processed cells or placebo are injected under electromechanical guidance into the affected areas of the left ventricle.",
      "label": "met"
    },
    {
      "criterion": "Follow-up testing, including quality of life and NOGA mapping, is done at the time of injection, as well as at 6 months.",
      "label": "unknown"
    },
    {
      "criterion": "This is a phase I, double blind trial to evaluate the use of Aldehyde Dehydrogenase-Bright (ALDHbr) in ischemic cardiomyopathy patients.",
      "label": "met"
    },
    {
      "criterion": "The study hypothesis is that transendocardial injections of autologous bone marrow cells in patients with end-stage ischemic heart disease is safe, can provide neovascularization, and can improve perfusion and myocardial contractility.",
      "label": "unknown"
    },
    {
      "criterion": "A maximum of 60 patients will be enrolled in the study.",
      "label": "met"
    },
    {
      "criterion": "At the end of 6 months, after the required testing has been completed, the patients will be told whether they were in the control group or not.",
      "label": "unknown"
    },
    {
      "criterion": "The patients in the control group will be given the option to crossover and actually receive stem cell injection.",
      "label": "met"
    },
    {
      "criterion": "At the time of crossover, which then becomes the baseline, patients will begin the follow-up with all testing including clinic visits for one year for a total of 18 months follow-up.",
      "label": "unknown"
    },
    {
      "criterion": "Canadian cardiovascular (CV) Class II-IV angina and/or congestive heart failure (CHF) symptoms",
      "label": "met"
    },
    {
      "criterion": "Ejection fraction less than or equal to 45%",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Age less than 18 or greater than 70",
      "label": "triggers"
    },
    {
      "criterion": "Atrial fibrillation",
      "label": "unknown"
    },
    {
      "criterion": "Severe valve disease",
      "label": "unknown"
    },
    {
      "criterion": "History of cancer in last 5 years",
      "label": "triggers"
    },
    {
      "criterion": "HIV positive; hepatitis B or C positive.",
      "label": "triggers"
    }
  ],
  "notes": "The patient is a 53-year-old man with Paget's disease of bone, confirmed by increased uptake of radioactive substance and urinary pyridinoline. He has bilateral swellings around the molars and several extraoral lesions on the head and face.",
  "_meta": {
    "topic_id": "74",
    "trial_id": "NCT00314366",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}